Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Tumor marker and application thereof

A cancer patient-responsive technology, applied in the field of tumor molecular biology, can solve problems such as poor response to neoadjuvant chemotherapy, altered cancer signal transduction, and unclear neoadjuvant chemotherapy

Active Publication Date: 2021-05-14
BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL +1
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, a significant proportion of GC cancer patients still respond poorly to neoadjuvant chemotherapy, and it is unclear how neoadjuvant chemotherapy alters cancer signaling and affects the tumor microenvironment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor marker and application thereof
  • Tumor marker and application thereof
  • Tumor marker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0185] Example: Verification of the response of C10orf71-related molecules to chemotherapy in patients with GC tumors

[0186] Patient Recruitment and Sample Cohorts

[0187]GC patients (>T2N+M0, UICC-AJCC 8th edition) for this inventive study were recruited at Peking University Cancer Hospital (Beijing, China) from 2015 to 2018. The study was performed in accordance with the Statement of Helsinki and was approved by the Ethics Committee of Peking University Cancer Hospital (IRB approval number, 2019KT05). All patients provided written informed consent prior to treatment, sample collection, and analysis. Tumors were collected by biopsy and matched to adjacent nontumor tissue before neoadjuvant therapy. For patients with no adjacent non-neoplastic tissue available, blood samples were taken instead. Then, all patients received a fluorouracil-based capecitabine / S-1+oxaliplatin regimen (XELOX [oxaliplatin, 130 mg / m2, intravenous injection, day 1; capecitabine, 1000mg / m2, orall...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a tumor marker and an application thereof, in particular to an application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in preparation of a product for predicting response of a cancer patient to neoadjuvant chemotherapy. According to the invention, the C10orf71 gene mutation is determined to be a key molecular characteristic of tumor response to neoadjuvant chemotherapy for the first time, and based on the technical scheme of the invention, the neoadjuvant chemotherapy has advantages in improvement of prognosis and determination of responsive patients before treatment, so that a better treatment scheme can be formulated.

Description

technical field [0001] The invention relates to the field of tumor molecular biology, in particular to a tumor cancer marker and its application. Background technique [0002] Neoadjuvant chemotherapy is a widely used treatment option for cancer patients, and several large clinical trials have shown that neoadjuvant chemotherapy has advantages in improving prognosis and identifying responsive patients before treatment begins, so better treatments can be formulated Program. However, a significant proportion of cancer patients do not respond well to neoadjuvant chemotherapy. To date, only certain clinical characteristics, such as age and preoperative weight loss, are available for patient selection, but with very limited functionality. Furthermore, it is unclear how neoadjuvant chemotherapy alters cancer signaling and affects the tumor microenvironment. [0003] Gastric cancer (GC) is one of the most common cancer types worldwide and the second most common cause of cancer-r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/12C07K14/47G01N33/574
CPCC12Q1/6886C07K14/47G01N33/57484C12Q2600/106C12Q2600/136C12Q2600/156
Inventor 季加孚李子禹高翔宇季序我梁晗彭鑫鑫李哲魏斌韦宝耶董宇
Owner BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com